Evidence map›Paper›PMID 25610731›Full record

ArticleOncoimmunology

The potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy.

Jennifer A Westwood, Phillip K Darcy, Michael H Kershaw

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Mouse Tumor Models for Advanced Cancer Immunotherapy.International journal of molecular sciences · 2020
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jennifer A WestwoodDivision of Cancer Research; Peter MacCallum Cancer Center ; East Melbourne, Australia.
Phillip K DarcyDivision of Cancer Research; Peter MacCallum Cancer Center ; East Melbourne, Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Prahran, Australia.
Michael H KershawDivision of Cancer Research; Peter MacCallum Cancer Center ; East Melbourne, Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Prahran, Australia.
Peter MacCallum Cancer Centre · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This commentary provides the authors' perspective on the article "Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice", published in PLoS ONE. It also discusses the caveats of using subcutaneous tumors to model the treatment of human cancers versus orthotopic mouse models that more closely mimic human disease.

Indexed as

cancerimmunotherapymouse modelorthotopicpreclinical

Identifiers

PMID25610731
PMCPMC4292559
OpenAlexW1968645192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.